Position in GRFS
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$57,362
+$48,300 QoQ
Shares Held
8,102
+617.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#109
of 164 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026NATIONAL BANK OF CANADA /FI/ holds $2,503,359,774 across 18 Drug Manufacturers - General names. GRFS ranks #15 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
692,569 | $830,688,102 | |
| 2 | JNJ |
Johnson & Johnson
|
1,312,753 | $333,399,877 | |
| 3 | MRK |
Merck & Co., Inc.
|
2,433,801 | $312,743,428 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
1,946,858 | $245,966,038 | |
| 5 | ABBV |
AbbVie Inc.
|
850,973 | $214,138,842 | |
| 6 | AMGN |
Amgen Inc
|
430,230 | $155,794,886 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
2,580,079 | $148,664,149 | |
| 8 | AZN |
Astrazeneca PLC
|
447,620 | $84,877,702 |
All Filings in GRFS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $57,362 | 8,102 | Shares | Defined | 2026-08-10 | |
| 2026-03-31 | $9,062 | 1,130 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $15,427 | 1,650 | Shares | Defined | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||